Clinical Trial Update: Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial of the modified virus VSV-IFNbetaTYRP1 in stage III-IV melanoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma
• Mucosal Melanoma
• Uveal Melanoma

Drugs mentioned

• VSV-IFNbetaTYRP1

Snippet

Sponsor: Mayo Clinic | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Status: TERMINATED